Managing toxicities associated with antiangiogenic biologic agents in combination with chemotherapy for metastatic colorectal cancer

Clinical Journal of Oncology Nursing

Volumn 17, Issue 4, 2013, Pages 425-433

  Grenon, Nina N ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84886925008     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/13.CJON.425-433     Document Type: Article

References (61)

1. Basch, E., Prestrud, A. A., Hesketh, P. J., Kris, M. G., Feyer, P. C., Somerfield, M. R.,... Lyman, G. H. (2011). Antiemetics: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology, 29, 4189-4198.
2. Beatty, K., Winkelman, C., Bokar, J. A., & Mazanec, P. (2011). Advances in oncology care: Targeted therapies. AACN Advanced Critical Care, 22, 323-334.
3. Blowers, E., & Hall, K. (2009). Managing adverse events in the use of bevacizumab and chemotherapy. British Journal of Nursing, 18, 351-356, 358.
4. Cassidy, J., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong R.,... Saltz, L. (2011). XELOX vs. FOLFOX-4 as first-line therapy for metastatic colorectal cancer: N016966 updated results. British Journal of Cancer, 105, 58-64.
5. Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L.,... Roccella, E. J. (2003). Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42, 1206-1252. doi: 10.1161/01. HYP.0000107251.49515.c2
6. Damron, B. H., Brant, J. M., Belansky, H. B., Friend, P. J., Samsonow, S., & Schaal, A. (2009). Putting Evidence Into Practice: Prevention and management of bleeding in patients with cancer. Clinical Journal of Oncology Nursing, 13, 573-583. doi:10.1188/09 CJON.573-583
7. Fuchs, C. S., Marshall, J., Mitchell, E., Wierzbicki, R., Ganju, V., Jeffery, M.,... Barrueco, J. (2007). Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. Journal of Clinical Oncology, 25, 4779-4786.
8. Gaya, A., & Tse, V. (2012). A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treatment Reviews, 38, 484-493. doi:10.10l6/j.ctrv. 2011.12.008
9. ® (bevacizumab) [Prescribing information]. Retrieved from http://www.gene.com/download/pdf/avastin- prescribing.pdf
10. Gerber, H. P., & Ferrara, N. (2005). Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinicai studies. Cancer Research, 65, 671-680.
11. Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R.,... & Benson, A. B. (2007). Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. Journal of Clinical Oncology, 25, 1539-1544.
12. Giantonio, B. J., Chen, H. X., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., & Benson, A. I. B. (2004). Bowel perforation and fistula formation in colorectal cancer patients treated on Eastern Cooperative Oncology Group (ECOG) studies E2200 and E3200. Journal of Clinical Oncology, 22(14, Suppl.), 3017.
13. Giantonio, B. J., Levy, D. E., O'Dwyer, P. J., Meropol, N. J., Catalano, P. J., & Benson, A. B. (2006). A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group study E2200. Annals of Oncology, 17, 1399-1403. doi:10.1093/annonc/mdll6l
14. Gobel, B. H. (2007). Nursing considerations of bevacizumab use in multiple tumor types. Oncology Nursing Forum, 34, 693-701.
15. Grenon, N. N., & Chan, J. (2009). Managing toxicities associated with colorectal cancer chemotherapy and targeted therapy: A new guide for nurses. Clinical Journal of Oncology Nursing, 13, 285-296. doi: 10.1188/09. CJON.285-296
16. Guan, Z. Z., Xu, J. M., Luo, R. C., Feng, F. Y., Wang, L. W., Shen, L.,... Xu, R. H. (2011). Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: A randomized phase III ARTIST trial. Chinese Journal of Cancer, 30, 682-689.
17. Harris, D. J., Eilers, J., Harriman, A., Cashavelly, B. J., & Maxwell, C. (2008). Putting Evidence Into Practice: Evidence-based interventions for the management of oral mucositis. Clinical Journal of Oncology Nursing, 12, 141-152. doi:10.1188/08. CJON.l4l-152
18. Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M.,... Rudge, J. S. (2002). VEGF-Trap: A VEGF blocker with potent antitumor effects. Proceedings of the National Academy of Sciences of the United States of America, 99, 11393-11398.
19. Horita, Y., Yamada, Y., Kato, K., Hirashima, Y., Akiyoshi, K., Nagashima, K.,... Shimada, Y. (2011). Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial. InternatiotialJournal of Clinical Oncology, 17, 604-609. doi:10.1007/s10147-011- 0331-2
20. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W.,... Kabbinavar, F. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine, 350, 2335-2342.
21. Jin, K., Shen, Y., He, K., Xu, Z., Li, G., & Teng, L. (2010). Aflibercept (VEGF Trap): One more double-edged sword of anti-VEGF therapy for cancer? Clinical and Translational Oncology, 12, 526-532.
22. Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G.... Bergsland, E. (2003). Phase II randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 21, 60-65.
23. Kabbinavar, F. F., Schulz, J., McCleod, M., Patel, T., Hamm, J. T., Hecht, J. R.,... Novotny, W. F. (2005). Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. Journal of Clinical Oncology, 23, 3697-3705. doi:10.1200/JC0.2005.05.112
24. Kopetz, S., Hoff, P. M., Morris, J. S., Wolff, R. A., Eng, C., Glover, K. Y.,... Heymach, J. V. (2010). Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. Journal of Clhiical Oncology, 28, 453-459. doi: 10.1200/JC0.2009.24.8252
25. Langewitz, W., Heydrich, L., Nübling, M., Szirt, L., Weber, H., & Grossman, P. (2010). Swiss Cancer League communication skills training programme for oncology nurses: An evaluation. Journal of Advanced Nursing, 66, 2266-2277.
26. Lyman, G. H., Khorana, A. A., Falanga, A., Clarke-Pearson, D., Flowers, C., Jahanzeb, M.,... Francis, C. W. (2007). American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. Journal of Clinical Oncology, 25, 5490-5505.
27. Mitchell, S. A., Beck, S. L., Hood, L. E., Moore, K., & Tanner, E. R. (2007). Putting Evidence Into Practice: Evidence-based interventions for fatigue during and following cancer and its treatment. Clinical Journal of Oncology Nursing, 11, 99-113.
28. Moore, K., Johnson, G., Fortner, B. V., & Houts, A. C. (2008). The AIM Higher Initiative: New procedures implemented for assessment, information, and management of chemotherapy toxicities in community oncology clinics. Clinical Journal of Oncology Nursing, 12, 229-238. doi:10.1188/08. CJON.229-238
29. Muehlbauer, P. M., Thorpe, D., Davis, A., Drabot, R., Rawlings, B. L., & Kiker, E. (2009). Putting evidence into practice: Evidencebased interventions to prevent, manage, and treat chemotherapy- and radiotherapy-induced diarrhea. Clinical Journal of Oncology Nursing, 13, 336-341. doi:10.1188/09. CJON.336-34l
30. 3): Health professional version. Retrieved from http://www.cancer.gov/cancertopics/pdq/supportivecare/oralcomplications/ HealthProfessional/page5
31. National Cancer Institute Cancer Dictionary, (n. d.a). Asthenia. Retrieved from http://www.cancer.gov/dictionary?cdrid=44787
32. National Cancer Institute Cancer Dictionary, (n. d.b). Fatigue. Retrieved from http://www.cancer.gov/dictionary?CdrID=321374
33. National Comprehensive Cancer Network. (2011). NCCN Clinical Practice Guidelines in Oncology: Venous thromboembolic disease. Retrieved from http://www.nccn.org/professionals/physician-gls/pdf/vte.pdf
34. National Comprehensive Cancer Network. (2012a). NCCN Clinical Practice Guidelines in Oncology: Antiemesis. Retrieved from http://www.nccn.org/ professionals/physician-gis/pdf/antiemesis.pdf
35. National Comprehensive Cancer Network. (2012b). NCCN Clinical Practice Guidelines in Oncology: Cancer- and chemotherapyinduced anemia. Retrieved from http://www.nccn.org/professionals/physjcian-gls/pdf/anemia.pdf
36. National Comprehensive Cancer Network. (2012c). NCCN Clinical Practice Guidelines in Oncology: Cancer-related fatigue. Retrieved from http://www.nccn.org/professionais/physician-gls/pdf/fatigue.pdf
37. National Comprehensive Cancer Network. (2012d). NCCN Clinical Practice Guidelines in Oncology: Myeloid growth factors. Retrieved from http://www.nccn.org/professionals/physician-gls/pdf/myeloid-growth.pdf
38. National Comprehensive Cancer Network. (2012e). NCCN Clinical Practice Guidelines in Oncology: Palliative care. Retrieved from http://www.nccn.org/ professionals/physician-gls/pdf/palliative.pdf
39. National Comprehensive Cancer Network. (2013). NCCN Clinical Practice Guidelines in Oncology: Colon cancer. Retrieved from http://www.nccn.org/ professionals/physician-gls/pdf/colon.pdf
40. Oncology Nursing Society. (2013a). Putting Evidence Into Practice. Diarrhea. Retrieved from http://www.ons.org/Research/PEP/Diarrhea
41. Oncology Nursing Society. (2013b). Putting Evidence Into Practice. Skin Reactions: Rash, palmar-plantar erythrodysesthesia, xerosis, paronychia, photosensitivity, and pruritus. Expert opinion Table. Retrieved from http://www.ons.org/Research/PEP/media/ons/docs/research/outcomes/skin/ expertopiniontable.pdf
42. Ouwerkerk, J., & Boers-Doets, C. (2010). Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. European Journal of Oncology Nursing, 14, 337-349. doi:10.10l6/j.ejon. 2010.03.004
43. Peterson, D. E., Bensadoun, R. J., & Roila, F. (2011). Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Annals of Oncology, 22(Suppl. 6), vi78-vi84. doi:10.1093/annonc/mdr391
44. ® (ziv-aflibercept) [Prescribing information]. Retrieved from http://products.sanofi.us/zaltrap/zaltrap.html
45. Saif, M. W. (2009). Managing bevacizumab-related toxicities in patients with colorectal cancer. Journal of Supportive Oncology, 7, 245-251.
46. Saltz, L. B., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R.,... Cassidy, J. (2008). Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. Journal of Clinical Oncology, 26, 2013-2019.
47. Schiffer, C. A., Anderson, K. C., Bennett, C. L., Bernstein, S., Elting, L. S., Goldsmith, M., Wagnon, A. H. (2001). Platelet transfusion for patients with cancer: Clinical practice guidelines of the American Cancer Society of Clinical Oncology. Journal of Clinical Oncology, 19, 1519-1538.
48. Sher, A., & Wu, S. (2011). Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis. Acta Oncologica, 50, 997-1005.
49. Siegel, R., Naishadham, D., & Jemal, A. (2012). Cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 62, 10-29.
50. Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L.,... Wolff, A. C. (2006). 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. Journal of Clinical Oncology, 24, 3187-3205. doi:10.1200/JC0.2006.06. 4451
51. Sobrero, A., Ackland, S., Clarke, S., Perez-Carrion, R., Chiara S., Gapski, J.,... Young, S. (2009). Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology, 77, 113-119. doi: 10.1159/000229787
52. Souglakos, J., Ziras, N., Kakolyris, S., Boukovinas, I., Kentepozidis, N., Makrantonakis, P.,... Polyzos, A. (2012). Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC). British Journal of Cancer, 106, 453-459. doi:10.1038/bjc.2011.594
53. Tang, P., Cohen, S. J., Bjarnason, G. A., Kollmannsberger, C., Virik, K., MacKenzie, M. J.... Moore, M. J. (2008). Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): A PMH phase II consortium trial. Journal of Clinical Oncology, 26(15, Suppl.), 4027.
54. Tew, W. P., Gordon, M., Murren, J., Dupont, J., Pezzulli, S., Aghajanian, C.,... Spriggs, D. R. (2010). Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clinical Cancer Research, 16, 358-366. doi:10.1158/1078-0432. CCR-09-2103
55. Tipton, J. M., McDaniel, R. W., Barbour, L., Johnston, M. P., Kayne, M.,... Ripple, M. L. (2007). Putting Evidence Into Practice: Evidence-based interventions to prevent, manage, and treat chemotherapy-induced nausea and vomiting. Clinical Journal of Oncology Nursing, 11, 69-78. doi:10.1188/07. CJON.69-78
56. Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausova, J., Macarulla, T.,... Allegra, C. (2012). Addition of aflibercept to FOLFIRI improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. Journal of Clinical Oncology, 30, 3499-3506. doi:10.1200/JC0.2012.42.8201
57. Verheu I. H. M., & Pinedo H. M. (2007). Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nature Reviews Cancer, 7, 475-485.
58. Viale, P. H. (2010). Incorporating new data on colorectal cancer into nursing practice. Clinical Journal of Oncology Nursing, 14, 92-100. doi: 10.1188/IO. CJON.92-IOO
59. Visovsky, C., Collins, M., Abbott, L., Aschenbrenner, J., & Hart, C. (2007). Putting Evidence Into Practice: Evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clinical Journal of Oncology Nursing, 11, 901-913. doi: 10.1188/07. CJON.901-913
60. Wilkes, G. M. (2005). Therapeutic options in the management of colon cancer: 2005 update. ClinicalJournal of Oncology Nursing, 9, 31-44. doi:10.1188/05. CJON.31-44
61. Woolery, M., Bisanz, A., Lyons, H. F., Gaido, L., Yenulevich, M., Fulton, S., & McMillan, S. C. (2008). Putting Evidence Into Practice: Evidence-based interventions for the prevention and management of constipation in patients with cancer. Clinical Journal of Oncology Nursing, 12, 317-337. doi:10.1188/08. CJON.317-337